• Go to navigation
  • Go to content
Welcome to Zomig.info!

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca
  • Zomig
  • Zomig Rapimelt
  • Zomig Nasal Spray

Main navigation

  • Home
  • Is it Migraine?
  • Learn About Migraine
  • Treating Migraine
  • Help For Your Migraine Patients
  • Scientific Opinions
    • Scientific Posters
      • Zolmitriptan
      • Zomig Rapimelt
      • Zomig Nasal Spray
  • Learn about Zomig
  • eDetailing
  • Prescribing Information
  • Migraine Glossary and Useful Links
  • References
  • About AstraZeneca
  • Sitemap

You are here

  • Home
  • Scientific Opinions
  • Scientific Posters
  • Zolmitriptan

  • Patient experience influences formulation preference: Results of three prospective studies with zolmitriptan

  • Primary care needs assessment for guidance on headache management

  • There is a strong unmet need for improved headache education among primary care physicians: results from a primary care needs assessment

  • Age-related trends and the placebo response rate in adolescent migraineurs

  • Patients who treat their migraine with zolmitriptan while the pain is still mild experience improved efficacy

  • Patient strategies for the management of migraine: interim results from an online market research study (MAZE Study phase IV)

  • Impact of migraine on sufferers and their families — MAZE* Study Phase III

  • What are patients looking for in a migraine therapy? – observations from the MAZE programme

  • Zolmitriptan conventional and orally disintegrating tablets achieve headache response as early as 30 minutes post-treatment: results of a pooled data analysis

  • Influence of baseline intensity of migraine and timing of drug administration on the efficacy of zolmitriptan oral tablet (2.5 and 5 mg)

  • Pages
  • 1
  • 2
  • Next

Not signed in



  • Register
  • Forgotten password?

Page tools

  • Print
  • Bookmark this page

Clinical Product Summary

  • Zomig Nasal Spray
  • Zomig Rapimelt

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008